Smith & Nephew announces new evidence, market updates on REGENETEN

Smith+Nephew announces new evidence and market updates that highlight the clinical performance of its REGENETEN Bioinductive Implant and support its further adoption. Substantial investment into research to expand access and indications have led to these important results designed to help surgeons treat more patients who suffer from rotator cuff tears and other tendon and extra-articular ligament injuries throughout the body. Two-year results of the MALLAMANGUITO RCT demonstrated a sustained 65% relative reduction in re-tear rates when using the REGENETEN Bioinductive Implant to augment repair of full-thickness rotator cuff tears: Two-year re-tear rates were 12.3% with the REGENETEN Implant vs. 35.1% with standard repair. These results build on previously reported 1-year results which have already made a significant impact in supporting patient access and adoption.